Sarepta Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Material agreementSep 23 →InsidersNo open-market buys. 2 insiders sold $417,410, 0 of 2 sales on a 10b5-1 plan.→HoldersBlackRock 18.0%State Street 8.4%Vanguard Portfolio 7.9%→PeersClosest companies: RLAY, VRDN, ORIC→
From the filings
Figures
- Revenue
- $1.87Blast 12 months
- Net income
- −$136.7Mlast 12 months
- Operating cash flow
- $175.3Mlast 12 months
- Cash and equivalents
- $571.1Mat the last balance sheet
- Total debt
- $847.6Mat the last balance sheet
- Shares outstanding
- 105.6M shareson issue